VTAK
Catheter Precision, Inc.
stockNYSEAMERICAN
advanced excimer laser-based vascular and dermatological therapies we are a commercial-stage medical device company leveraging our advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases. we believe our products enhance patients' quality of life by restoring blood-flow in arteries and clearing chronic skin conditions. we currently manufacture and market two lines of products: dabra catheter and laser is cleared by the u.s. fda as a tool for the minimally invasive endovascular treatment of vascular blockages resulting from lower extremity vascular disease, which includes peripheral artery disease (pad), which commonly occurs in the legs. pharos excimer laser pharos is designed for use in the treatment of inflammatory skin conditions and is fda cleared as a tool used in the treatment of psoriasis, atopic dermatitis, and leukoderma. our goal is to become the leading medical device company marketing excimer lasers as tools for the treatment of
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 0.15 | 2026-09-28 | +4.16% | -2.038 |
| 1M | 0.21 | 2026-09-04 | -27.24% | 1.934 |
| 3M | 0.77 | 2026-07-06 | -80.06% | -0.324 |
| 6M | 0.95 | 2026-04-06 | -83.91% | -0.937 |
| 1Y | 2.54 | 2025-10-06 | -93.98% | 0.721 |
| 2Y | 6.86 | 2024-10-04 | -97.77% | — |
| 5Y | 103.34 | 2023-08-18 | -99.85% | 0.576 |
Catheter Precision, Inc. (NYSEAMERICAN:VTAK) stock price today is $0.15, and today's volume is 1,305,541. VTAK is up 0.526% today. The 30 day average volume is 2.04M. VTAK market cap is $289,893 with 1.90M shares outstanding.